Sage Therapeutics Inc logo

Sage Therapeutics Inc

$ 46.57 +0.85 (+1.86%) 08:09 PM EST
P/E:
At Loss
P/B:
2.01
Market Cap:
$ 2.73B
Enterprise V:
$ 1.34B
Volume:
522.20K
Avg Vol (2M):
485.25K
Also Trade In:
Volume:
522.20K
Market Cap $:
2.73B
PE Ratio:
At Loss
Avg Vol (2-Month):
485.25K
Enterprise Value $:
1.34B
PB Ratio:
2.01

Business Description

Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.
Name Current Vs Industry Vs History
Cash-To-Debt 101.23
Equity-to-Asset 0.93
Debt-to-Equity 0.01
Debt-to-EBITDA -0.03
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 13.61
Distress
Grey
Safe
Beneish M-Score 82.97
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 70.89
9-Day RSI 65.5
14-Day RSI 62.92
6-1 Month Momentum % -3.96
12-1 Month Momentum % -8.22

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.7
Quick Ratio 14.7
Cash Ratio 13.98
Days Payable 3355.78

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -7.9

Financials (Next Earnings Date:2023-02-16)

SAGE's 30-Y Financials

How Sage Therapeutics Inc (SAGE) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SAGE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 6.464
EPS (TTM) ($) -8.63
Beta 1.04
Volatility % 27.88
14-Day RSI 62.92
14-Day ATR ($) 1.871726
20-Day SMA ($) 43.63475
12-1 Month Momentum % -8.22
52-Week Range ($) 27.36 - 49.56
Shares Outstanding (Mil) 59.49

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sage Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Sage Therapeutics Inc Stock Events

Event Date Price($) Daily Change %
No Event Data

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1